Datametrex AI (TSXV: DM) has expanded its target market for COVID-19 test kits. The company announced this morning that two of its test kit offerings have recently received US FDA authorization under Emergency Use Authorizations for Medical Devices (EUA).
The first kit, produced by Seasun Biomaterial, is a 20 minute rapid Nucleic Acid test kit. The kit, referred to as AQ-TOP COVID-19 Rapid Detection Kit, expedites the process of testing via reduced testing times which assists in detecting the virus earlier than other offerings. The kit also provides a more accurate prediction of positive cases.
The second offering is that of the popular 1drop Inc test kit which has been in high demand from Canadian mining firms, as demonstrated by yesterdays announcement of a $450,000 purchase order. 1drop’s 1copy COVID-19 qPCR Multi Kit has also seen FDA authorization under the EUA program with the US FDA. The multi kit is also a nucleic test kit, providing results in less than two hours via the use of swabs.
The company now has three different COVID-19 test kit offerings that have received FDA approval under the Coronavirus Disease 2019 Emergency Use Authorizations for Medical Devices that it is able to sell across the US. In addition to the 1copy and AQ-Top test kits, the company also has the rights to sell the Seasun U-TOP COVID-19 Detection Kit.
Datametrex AI last traded at $0.12 on the TSX Venture.
FULL DISCLOSURE: Datametrex AI is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Datametrex AI on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
